Otenaproxesul

Otenaproxesul is a analgesic and anti-inflammatory drug being developed by Antibe Therapeutics.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Otenaproxesul is a analgesic and anti-inflammatory drug being developed by Antibe Therapeutics. An NSAID structurally derived from naproxen, in 2016 it received approval to commence phase II clinical trials as a treatment for osteoarthritis after completing phase I clinical trials in 2015.

In 2018, the drug completed trials for gastrointestinal safety, and in 2020 completed phase IIb trials on efficacy of pain reduction. Initial phase III clinical trials in 2021 failed to meet the necessary criteria to advance to the next phase. Other in vivo studies have demonstrated a reduction in zymosan-induced pain and inflammation and cytokine-induced bone loss.

Preclinical studies have also investigated the treatment of melanoma, intestinal cancer, and periodontitis.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1330449731 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

4 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.